期刊
EUROPEAN UROLOGY FOCUS
卷 7, 期 2, 页码 373-380出版社
ELSEVIER
DOI: 10.1016/j.euf.2019.12.001
关键词
Epidermal growth factor receptor; Renal cell carcinoma; RNA splice variants; RNA sequencing
资金
- Urology Care Foundation Research Scholar Award Program
- Society for Urologic Oncology
- Alpha Omega Alpha Carolyn L. Kuckein Student Research Fellowship
- DeBartolo Family
This study characterized a novel EGFR splicing alteration in renal cell carcinoma, which was specific to patients with advanced ccRCC and associated with poor response to immunotherapy. High expression of EGFR_pr20CTF correlated with lower survival rates and <16 months average survival in patients.
Background: Accumulating evidence suggests that alternative RNA splicing has an important role in cancer development and progression by driving the expression of a diverse array of RNA and protein isoforms from a handful of genes. However, our understanding of the clinical significance of cancer-specific RNA splicing in renal cell carcinoma (RCC) is limited. Objective: To characterize and validate a novel oncogene RNA splicing event discovered in patients with RCC and to correlate expression with clinical outcomes. Design, setting, and participants: Using DNA and RNA sequencing, we identified a novel epidermal growth factor receptor (EGFR) splicing alteration (EGFR_pr20CTF) in RCC tumor tissue. Outcome measurements and statistical analysis: We confirmed the frequency and specificity of the EGFR_pr20CTF variant by analyzing cohorts of patients from our institution (n = 699) and The Cancer Genome Atlas (TCGA; n = 832). Furthermore, we analyzed its expression in tumor tissue and a human kidney cancer cell line using reverse transcriptase-polymerase chain reaction. Variant expression was also correlated with survival and response to systemic therapy. Results and limitations: EGFR_pr20CTF expression was identified in 71.7% (n = 71/99) of patients with RCC in our institutional cohort and in 56.7% (n = 279/492) of patients in the TCGA cohort. EGFR_pr20CTF was found to be specific to clear cell renal cell carcinoma (ccRCC), occurring in <0.2% of non-RCC tumors (n = 2/1091). High levels of EGFR_pr20CTF correlated with lower survival at 48 mo following immunotherapy (p = 0.036). The average survival in patients with high EGFR_pr20CTF expression was <16 mo. Conclusions: The EGFR_pr20CTF RNA splice variant occurs frequently, is specific to patients with advanced ccRCC, and is associated with a poor response to immunotherapy. Patient summary: Cancer-specific RNA alternative splicing may portend a poor prognosis in patients with advanced clear cell renal cell carcinoma. Further investigation will help clarify whether EGFR_pr20CTF can be used as a biomarker for this patient population. (C) 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据